Unani Medicine Plant Project Report: Industry Trends, Plant Setup, Machinery, Raw Materials, Investment Opportunities, Cost and Revenue

Note: The regulatory items below outline the typical compliance architecture for this project type. Specific BIS / IS standard numbers, licence thresholds, GST HSN codes, and scheme rates referenced should be verified with the issuing authority (see References & primary sources at the bottom of this page). KAMRIT's compliance team confirms each item against current notifications during project engagement.

Unani medicine plant sits under India's strictest regulatory regime (CDSCO at the centre, state Drug Controllers, plus WHO-GMP and Schedule M). For ₹2.0 crore - ₹32 crore CapEx this DPR captures:

• WHO-GMP and Schedule M revised standards compliance
• Plant Master File (PMF) and Site Master File (SMF) for export dossier
• NABL accreditation for QC lab, BSL-2/BSL-3 containment certification where applicable
• Bio-medical waste authorisation under BMW Rules 2016
• PLI Bulk Drugs (₹15,000 cr) or PLI Medical Devices (₹3,420 cr) participation
• NABH / NABL accreditation if the project includes a clinical or diagnostic arm
• Manufacturing licence under the Drugs and Cosmetics Act 1940 (Form 25/28/28A by category)

KAMRIT files and tracks every one of these approvals end-to-end in the Tier 3 Execution Partnership, including dossier preparation, regulator interaction, fee remittance, and the renewal calendar through year three of operations.

The Indian traditional medicine and herbal remedies sector is structurally bifurcated into organized and unorganized segments. The organized sector comprises roughly 20% to 30% of the total traditional medicinal plant and herbal formulation market, dominated by GMP (Good Manufacturing Practices) certified entities, institutional players, and standardized processing units that adhere to Ministry of AYUSH regulatory frameworks. The unorganized sector accounts for the remaining majority share, reflecting the sector's largely artisanal roots.

India's overall herbal medicine market, inclusive of Unani, Ayurveda, Siddha, and Homeopathy, reached USD 4.92 billion in 2025 per Intel Market Research. The broader Indian AYUSH and alternative medicine market reached USD 24.87 billion in 2025 and USD 26.53 billion in 2026. The global traditional medicine market is valued at USD 230.70 billion in 2026, projected to reach USD 392.83 billion by 2033.

Globally, the medicinal herbs market is valued at USD 253.60 billion in 2026 and forecast at USD 540.33 billion by 2033 at a CAGR of 11.4%. The global OTC herbal and traditional medicines market was valued at USD 179.94 billion in 2026 and forecast at USD 288.31 billion by 2035 at a CAGR of 5.38%. Unani medicine benefits from 98% domestic sourcing of raw herbal inputs.

Between the 2015-16 and 2020-21 periods, NAM interventions brought 456,305 hectares under medicinal and aromatic plant (MAP) cultivation, establishing a robust raw-material base. Industry clusters also include nine approved AYUSH industry clusters across India with total funding of INR 83.70 crores, including INR 10.00 crores at Lepakshi Ayush Park in Andhra Pradesh, INR 10.00 crores at Ayurpark Health Care in Karnataka, INR 10.00 crores at CARE Keralam in Kerala, and corresponding allocations in Maharashtra and other states.

Project-specific demand drivers

• PLI Bulk Drug and Medical Devices
• US generics export opportunity
• Health insurance penetration rising
• Chronic disease burden growth
• Hospital capex expansion in Tier-2/3
• Telemedicine and digital health adoption

Modern Unani medicine manufacturing technology integrates classical formulation methods with advanced extraction and quality-assurance processes. Extraction techniques include Supercritical Fluid Extraction (SFE) using carbon dioxide for gentle and residue-free active constituent isolation, Soxhlet hot percolation, and automated steam distillation for preparing Araq (distillates) and Usara (essences), key Unani galenical forms. AI and ML integration for drug discovery and natural antibiotic screening has been documented in literature from 2024 (Nasution et al., 2024), with adoption accelerating between 2024 and 2026.

The manufacturing sector is transitioning from traditional batch paradigms toward continuous manufacturing and Process Analytical Technology (PAT) for real-time process monitoring. Raw material authentication now routinely employs DNA barcoding to precisely identify botanical species and guard against adulteration and substitution. Quality standards frameworks include GMP compliance and ISO 14001 certification for environmental management and sustainable processing.

Energy-intensive manufacturing stages, including drying, heating, and cooling, are being optimized to reduce kilowatt-hour consumption and minimize greenhouse gas emissions. Additionally, solar integration in distillation units yields energy retrofit savings of up to 30%, while direct farm sourcing can reduce expenses by up to 20%.

The Means of Finance recommendation for this project aligns with its CapEx envelope of ₹2.0 crore to ₹32 crore and the borrower's risk profile. For the ₹2.0-5.0 crore CapEx band (small-scale Unani formulation unit, tablet-capsule focus, 2-5 TPD capacity), KAMRIT recommends a Debt:Equity ratio of 70:30, with PMEGP (Prime Minister's Employment Generation Programme) term loans from SIDBI and state KVIC channels providing up to 35 percent of project cost at 8-12 percent interest, supplemented by CGTMSE guaranteed collateral-free working capital limits from member banks including SBI, Bank of Baroda, and HDFC Bank at prime-linked rates. For the ₹5.0-15.0 crore band (mid-scale unit with extraction capability, 5-15 TPD), a 65:35 debt-equity structure leverages SIDBI's SIDBI Clean Tech Fund and EXIM Bank's line of credit for export-oriented production, with ICICI Bank and Axis Bank's MSME verticals offering blended rates of 9.5-11.5 percent on composite loans. For the ₹15.0-32.0 crore band (integrated facility with API synthesis, in-house quality control laboratory, and cold-chain logistics), KAMRIT structures a 60:40 debt-equity recommendation incorporating PLI Scheme benefits (4 percent incentive on incremental sales for 5 years, applied against project debt service), NABARD refinan cing at 5-6 percent for agricultural raw-material procurement components, and IREDA green finance linkage for renewable energy infrastructure. Working capital cycle of 65-85 days reflects the extended raw material sourcing cycle for Unani botanicals (many imported from Iran, Afghanistan, and Morocco via EXIM channels), with inventory norms of 45-60 days for active ingredients, 15-25 days for packaging materials, and 30-45 days for finished goods buffer stock to absorb seasonal demand peaks (Ramadan, winter respiratory ailments surge).

Unani medicine manufacturing in India faces several material risks that investors must weigh against the sector's growth potential. The most critical supply chain vulnerability is the heavy reliance on wild harvesting: approximately 90% of medicinal plants utilized by the traditional herbal industry, including Unani and Ayurveda, are sourced from wild populations rather than cultivated sources, according to Ved and Goraya (2007) and Seethapathy et al. (2014).

This dependency creates significant biodiversity, seasonal, and price volatility risks. Adulteration and substitution rates remain elevated in the sector, compromising product integrity and consumer trust, though DNA barcoding adoption is helping mitigate this. The unorganized sector's dominance over the organized segment also creates quality-assurance challenges at the industry level.

Import dependency for major raw herb materials persists despite 98% domestic sourcing claims at the aggregate level, exposing manufacturers to foreign exchange and trade policy risks. Cultivation deficits, particularly for high-value species like Withania somnifera (Ashwagandha) and other key Unani drugs, can create bottlenecks as demand scales. Regulatory compliance costs, while standardized through Schedule T and GMP, require ongoing investment in qualified personnel, infrastructure, and periodic audits.

Market fragmentation across a largely unorganized base of 70% to 80% of participants also intensifies price competition and margin pressure for new entrants. Export growth, while accelerating (5.86% value increase in 2024-25), remains dependent on evolving international phytopharmaceutical regulations and quality-assurance certifications. The 12% GST rate on packaged Unani medicaments, while standard, must be priced into consumer-facing margins.